AN EVIDENCE-BASED APPROACH TO MANAGING ACS PATIENTS FOR OPTIMAL CARE

FACULTY

C. Michael Gibson, MS, MD, FACC
Director TIMI Core Laboratories and Data Coordinating Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Steven R. Steinhubl, MD (Moderator)
Associate Professor of Medicine
Director of Cardiovascular Education & Clinical Research
University of Kentucky Chandler Medical Center
Lexington, KY

Electronic newsletter now available:
Managing Patients With Acute Coronary Syndromes: Evidence-Based Approaches to Improve STEMI and UA/NSTEMI Outcomes



Read frequently asked questions submitted by your peers.

PURPOSE STATEMENT

An Evidence-Based Approach to Managing ACS Patients for Optimal Care will discuss current ACS treatment guidelines and recent clinical trials, and evaluate the role of antithrombin and antiplatelet therapy in the management of STEMI and NSTE-ACS patients.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Discuss the current guideline recommendations for antithrombin and antiplatelet therapy for the adjunctive treatment of STEMI and NSTE-ACS.
• Summarize the results of the most recent trials of antithrombin and antiplatelet agents for use in the management of STEMI and NSTE-ACS patients.
• Incorporate recent trial results into an evidenced-based management plan for patients with STEMI or NSTE-ACS
  

TARGET AUDIENCE

This activity is intended for clinical and interventional cardiologists, as well as emergency medicine physicians and other healthcare professionals interested in the management of acute coronary syndromes.

ACCREDITATION INFORMATION

Expiration date: June 26, 2008

Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses (CBRN): Med-IQ is a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hours.

Pharmacists:
1 contact hour (0.100 CEU) of credit for pharmacists. Pharmacy credits made possible by the cosponsorship of Med-IQ and Medical Education Collaborative (MEC). MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. For questions about pharmacy accreditation, contact MEC at 303 420 3252 or e-mail inquire@mecce.org. Enduring ACPE # 815-999-07-018-H01. The program is designed for all pharmacists.

                  

 Other Credit Information
Nurse Practitioners:  Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 Credit^TM.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit^TM for the PRA from organizations accredited by ACCME.

Disclosure Policy
It is the policy of Med-IQ that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentation(s). Individuals who refuse to disclose will be disqualified from all aspects associated with this CME activity. Med-IQ has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

C. Michael Gibson
Fees received for promotional/non-CME activities: sanofi-aventis U.S., GlaxoSmithKline, The Medicines Co., Genentech
Contracted research: sanofi-aventis U.S.

Steven R. Steinhubl
Consulting fees/advisory boards: The Medicine Company, Eli Lilly and Company, sanofi-aventis U.S. Daiichi Sankyo, Inc.

Med-IQ Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.

All other employees of Med-IQ have no financial relationships to disclose.

MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.

Acknowledgement of Commercial Support
This educational series is supported by an educational grant from sanofi-aventis U.S.